XNCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XNCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Xencor's Average Total Inventories for the three months ended in Mar. 2024 was $0.0 Mil. Xencor's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.0 Mil.
The historical rank and industry rank for Xencor's Days Inventory or its related term are showing as below:
Xencor's Days Inventory stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Xencor's Inventory-to-Revenue for the three months ended in Mar. 2024 was 0.00.
The historical data trend for Xencor's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Xencor Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Days Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Xencor's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xencor's Days Inventory distribution charts can be found below:
* The bar in red indicates where Xencor's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Xencor's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as
Days Inventory (A: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
Xencor's Days Inventory for the quarter that ended in Mar. 2024 is calculated as:
Days Inventory (Q: Mar. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor (NAS:XNCR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Xencor's Inventory Turnover for the three months ended in Mar. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xencor's Inventory to Revenue for the three months ended in Mar. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 12.805 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Xencor's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Bassil I Dahiyat | director, officer: PRESIDENT & CEO | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Barbara Klencke | director | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
Allen Yang | officer: SR. VICE PRESIDENT & CMO | C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Celia Eckert | officer: VP, GENERAL COUNSEL | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
John R Desjarlais | officer: SR. VICE PRESIDENT & CSO | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
John J Kuch | officer: SR. VICE PRESIDENT & CFO | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Nancy Valente | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Richard J Ranieri | director | 3005 FIRST AVE, SEATTLE WA 98121 |
Ellen Feigal | director | C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Yujiro S Hata | director | C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Dagmar Rosa-bjorkeson | director | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Alan Bruce Montgomery | director | 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660 |
Kevin Charles Gorman | director | 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
Kurt A Gustafson | director | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Stafford John S Iii | 10 percent owner | 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604 |
From GuruFocus
By Business Wire Business Wire • 04-17-2023
By Business Wire Business Wire • 05-08-2023
By PRNewswire PRNewswire • 01-05-2023
By Business Wire Business Wire • 05-01-2023
By Business Wire • 09-27-2023
By Business Wire Business Wire • 05-30-2023
By Business Wire Business Wire • 02-16-2023
By Business Wire Business Wire • 04-26-2023
By Business Wire Business Wire • 01-09-2023
By Business Wire Business Wire • 11-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.